BRCA1/2 mutations and recently described constitutional FMR1 genotypes have, independently, been associated with prematurely diminished ovarian reserve. Whether they interrelate in distribution, and whether observed effects of BRCA1/2 and FMR1 on ovaries are independent of each other, is unknown. In a prospective comparative cohort study, we, therefore, investigated the distribution of constitutional FMR1 genotypes, normal (norm), heterozygous (het) and homozygous (hom), and of their respective sub-genotypes (high/low), in 99 BRCA1/2 mutation-positive women and 410 female controls to determine whether distribution patterns differed between study and control patients. In contrast to controls, BRCA1/2 carriers demonstrated almost complete absence of all constitutional FMR1 genotypes except for sub-genotypes with low (CGG n<26) alleles. Cross tabulation between BRCA1/2-positive patients and controls confirmed significant group membership, related to FMR1 distribution (P<0.0001). These results offer as most likely explanation the conclusion that BRCA1/2 mutations are embryo-lethal, unless rescued by low (CGG n<26) FMR1 sub-genotypes, present in approximately one quarter of all women. Women with low FMR1 sub-genotypes, therefore, should reflect increased BRCA1/2-associated cancer risks, while the remaining approximately 75 percent should face almost no such risks. If confirmed, this observation offers opportunities for more efficient and less costly BRCA1/2 cancer screening. The study also suggests that previously reported risk towards prematurely diminished ovarian reserve in association with BRCA mutations is FMR1-mediated, and offers a possible explanation for the so-called “BRCA paradox” by raising the possibility that the widely perceived BRCA1/2-associated tumor risk is actually FMR1-mediated.
Citation: Weghofer A, Tea M-K, Barad DH, Kim A, Singer CF, et al. (2012) BRCA1/2 Mutations Appear Embryo-Lethal Unless Rescued by Low (CGG n<26) FMR1 Sub-Genotypes: Explanation for the “BRCA Paradox”? PLoS ONE 7(9): e44753. doi:10.1371/journal.pone.0044753
Editor: Anthony W.I. Lo, The Chinese University of Hong Kong, Hong Kong
Received: June 1, 2012; Accepted: August 7, 2012; Published: September 12, 2012
Copyright: © Weghofer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funds from the not-for-profit Foundation for Reproductive Medicine, New York, N.Y., 10021, USA and intramural funds from the Center for Human Reproduction (CHR) – New York, a for-profit fertility and research center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: N.G., A.W. and D.H.B. have in the past received research support, speakers’ honoraria and travel funds from EDM Serono (now Merck-Serono), Organon Pharmaceutical (now Schering Plough), Ferring Pharmaceuticals and Bard Medical, none, however, related to the subject of this paper. N.G. and D.H.B. are listed as co-inventors on pending U.S. patent applications, claiming diagnostic benefits from determining of ovarian FMR1 genotypes and sub-genotypes in association with female infertility. The patent claims are (1) Diagnostic relevance of CGG repeat numbers on the FMR1 gene in predicting functional ovarian reserve over time (i.e., ovarian aging patterns); (2) Newly described, so-called “ovarian” genotypes and sub-genotypes, based on a normal range of 26–34 CGG repeats as “normal” range; (3) Diagnostic relevance of these newly described genotypes and sub-genotypes in defining specific ovarian aging patterns and relevance to defining autoimmune risk. N.G. is the owner of The CHR, and A.K. and D.H.B. are employed there. A.W. is an associate visiting scientist at The CHR. The CHR was a funder of this study and where this research was conducted. The medical corporation, however, exerted no influence on this study. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
The fragile X mental retardation 1 (FMR1) gene, located on the long arm of the X chromosome (Xq27.3) at base pairs 146,801,200 to 145,840,302, contains a repetitive DNA segment, the CGGn trinucleotide. The gene has, historically, primarily been investigated due to associated neuro-psychiatric risks at so-called premutation range CGG expansions (approximately CGG n = 55–200) and at full mutation range (CGG n>200), the so-called fragile X syndrome .
In women, the premutation range genotype of FMR1 has for decades been known associated with greatly increased risk towards premature ovarian failure (POF), often also called primary ovarian insufficiency (POI) . The gene until recently was, however, not known for any specific associated ovarian phenotypes. This changed with the description of newly described constitutional, so-called ovarian genotypes of FMR1, with distinct phenotypical ovarian aging patterns, associated with prematurely diminished functional ovarian reserve and other associations , .
These newly described ovarian genotypes of FMR1 were based on definition of a normal CGGn range of 26–34 (median CGG n = 30) , later confirmed to be identical in all races, though in outliers (het and hom genotypes and sub-genotypes) demonstrating distinct distribution differences between races , . The median of CGG n = 30 corresponded with the switching point between positive and negative message and peak translation of the gene product of FMR1, as previously reported by Chen et al .
Observing ovarian responses during in vitro fertilization (IVF), Oktay et al suspected in young BRCA mutation carriers with breast cancer a similar impairment in functional ovarian reserve as had been previously observed in association with certain FMR1 genotypes and sub-genotypes and, indeed, demonstrated such an association with BRCA1 . Considering potential overlaps in BRCA1/2 and FMR1 genotypes and sub-genotypes, observed associations with BRCA1/2, however, do not necessarily have to be causal and, at least theoretically, could be related to overlapping FMR1 genotypes and sub-genotypes.
The commonality of prematurely diminished ovarian reserve, reported independently for BRCA mutations and the FMR1 gene, therefore, led us to investigate to what degree BRCA1/2 and FMR1 genotypes and sub-genotypes interrelate in distribution, and whether observed BRCA effects on ovarian reserve may be FMR1-mediated. As this study will demonstrate, the relationship between BRCA1/2 and the FMR1 gene was found to be surprisingly interdependent, raising a number of new biological questions of importance.
Coordination of research efforts between Austrian and U.S. centers involved one author (A.W.). BRCA1/2 and FMR1 data of Austrian BRCA1/2-positive patients were obtained in Austria, and without further analysis anonymized forwarded to New York investigators (D.H.B., A. K., N. G.) for statistical analyses.
The study involved two distinct patient populations: (i) 99 Austrian female BRCA1 or BRCA2 mutation-positive patients. Their BRCA1/2 testing was performed at the Medical University Vienna, Vienna, Austria, while their FMR1 assays were performed at the Medical University Graz, Graz, Austria. (ii) 410 female infertility patients, whose anonymized clinical information, including FMR1 testing results, were stored in the electronic research database of the Center for Human Reproduction in New York, U.S.A. An infertile female population like the one presented here, previously was shown to demonstrate similar CGG count distributions as a general population , .
An initial statistical analysis of the Austrian data set, because of here reported rather extraordinary findings, raised questions about reproducibility of Austrian and U.S. FMR1 results. The Austrian laboratory was, therefore, requested to provide random anonymized results of a patient population reflecting the whole CGG spectrum. When the U.S. investigators analyzed these 105 additional controls, FMR1 genotypes and sub-genotypes did not differ significantly in either median or distribution between 25th and 75th percentiles from infertile U.S. controls, thus confirming reproducibility and compatibility of Austrian and U.S. FMR1 analyses.
BRCA1/2 and FMR1 analyses of the Austrian study group were performed in Vienna (BRCA1/2) and Graz (FMR1), Austria, respectively. Until and inclusive of 2008, BRCA1/2 analyses were performed by denaturation high performance liquid chromatography, as previously reported by the laboratory . After 2008, DNA sequencing, with use of chain-terminating inhibitors, was utilized .
FMR1 analyses in Austria were performed by Southern blot hybridization and polymerase chain reaction (PCR), as previously reported from this laboratory . New York FMR1 analyses were performed by commercial assays, as previously reported –.
Austrian FMR1 data were reported for both alleles as CGG n, and in New York converted to the recently reported format of ovarian genotypes and sub-genotypes , , . In brief, it is based on a normal range of CGG n = 26–34, with median of 30 repeats. Women, therefore, can have the following genotypes: normal (norm) if both alleles are in normal range; heterozygous (het), if one allele is in and one outside of normal range; and homozygous (hom) if both alleles are outside normal range. Het and hom genotypes can then be further subdivided, depending whether abnormal alleles are above (high) or below (low) normal range into het-norm/high and het-norm/low and hom-high/high, hom-high/low and hom-low/low sub-genotypes. Because of the small number of hom patients, they are not sub-divided into sub-genotypes in this study.
Institutional Review Board (IRB) Approvals
The Ethikkommission der Medizinischen Universität Wien, an IRB at the University Vienna, Austria, approved analysis of BRCA1/2 patients. Written consents were obtained from all participants. The CHR’s IRB (Institutional Review Board, the Center for Human Reproduction) approved data analysis of the U.S. control group. CHR patients, at time of initial consultation, sign an informed consent, which allows for review of medical records for research purposes as long as patient anonymity and confidentiality of the medical record are maintained. These conditions were met, and the study, therefore, qualified for expedited review. Patients, undergoing FMR1 testing at CHR, in addition, sign a genetic testing-specific consent, and all clinical and research staff at CHR, in concordance with federal HIPAA rules, in writing commit to maintaining confidentiality of medical record and anonymity of patients.
Proportions of FMR1 genotypes and sub-genotypes were compared between the two study groups using cross-tabulations and calculations of Chi-square and Cramer’s V statistics. When comparing CGG n as a continuous function between the groups, nonparametric testing was used because CGG n in populations tends to be positively skewed. Mann-Whitney U tests were conducted to evaluate differences between the two groups on median change in CGG n of both alleles.
All statistical calculations were performed utilizing SPSS, version 18 (Chicago, Illinois).
Controls demonstrated a similar FMR1 genotype and sub-genotype distribution to previously reported populations ,  (Figure 1), with normal (norm), heterozygous (het) and homozygous (hom) genotypes of 58.0, 36.1 and 5.9 percent, respectively. The expected distribution was also observed with sub-genotypes, with het-norm/high at 15.6 and het-norm/low at 20.5 percent, each, and also follows that in general populations , .
Figure 1. Distribution of FMR1 genotypes and sub-genotypes in women with BRCA1/2 mutations (black bars) and U.S. (gray) comparison group; * within each category denotes significance at P<0.05. Noteworthy are the excess of het-norm/low and complete absence of het-norm/high in FMR1 sub-genotypes in BRCA1/2 mutation carriers, and the very low prevalence of women with norm FMR1 genotype.
A numerical presentation of these data is presented in (a), In description of genotypes norm stands for normal, het for heterozygous and hom for homozygous. In description of sub-genotypes high stands for CGG n>34 and low for CGG n<26.doi:10.1371/journal.pone.0044753.g001
Table 1 offers a detailed description of BRCA1/2 mutations in the study group. BRCA1/2 carriers presented with distinctively different FMR1 genotype and sub-genotype distributions (Figure 1): An overwhelming majority of BRCA1/2 patients exhibited the het-norm/low FMR1 sub-genotype (74.0% BRCA1 and 83.7% BRCA2, respectively). Combined, 78.8 percent of women who were BRCA1 or BRCA2 positive, thus, exhibited the het-norm/low FMR1 sub-genotype. In further stark contrast to controls, none of the BRCA1/2 carriers demonstrated the het-norm/high FMR1 sub-genotype.
Table 1. Individual BRCA1/2 mutations in study group.doi:10.1371/journal.pone.0044753.t001
BRCA1/2- positive patients also demonstrated almost no norm genotypes, by far the most prevalent genotype in controls (Figure 1) and in previously investigated populations , : Only 10.0 and 2.0 percent of BRCA1 and BRCA2 patients, respectively (combined 6.1%), demonstrated a norm FMR1 genotype.
The hom genotype was mildly overrepresented in BRCA1 and BRCA2 carriers (16.0% and 14.3%, respectively; combined, 15.2%). Numbers were, however, too small for meaningful assessments of individual hom sub-genotypes, and this group of patients was, therefore, collapsed. Controls had not been investigated for BRCA1/2.
In comparing distribution of FMR1 genotypes and sub-genotypes between BRCA1/2 patients and controls (with hom sub-genotypes collapsed), group membership was significantly related [x2 (6, N = 614) = 158.71; P<0.0001). Non-parametric testing (Mann-Whitney U test)] confirmed statistically significant differences in median change for CGGn on the low count allele of the FMR1 gene between both patient groups; with follow up tests (Dunn’s Method) indicating significant differences between groups (Figure 2a & b).
Figure 2. Distribution on both FMR1 alleles, of CGG n in BRCA1/2 mutation carriers as well as U.S. controls in form of scattergrams.
Horizontal and vertical parallel lines in scattergrams define the norm distribution area (CGG n = 26–34), with areas below and above representing low and high, sub-genotypes, respectively; a represents higher and lower count allele, respectively, for individual patients. Only the lower count allele varied significantly between the two groups (Mann-Whitney U test, P<0.001). Scattergrams, as well as a, demonstrate graphically the significant shift towards low FMR1 sub-genotypes, especially on the lower count allele of BRCA1/2 mutation carriers. In a - - - represents mean; ______ represents median.doi:10.1371/journal.pone.0044753.g002
For the lower CGG n allele, in most cases representative of a low FMR1 genotype/sub-genotype, values amongst the two groups were also significantly different [Mann-Whiney U = (Mean Rank 83.37low, 296.44 high; Z = −13.10; P = 0.001)]. The higher count CGG n allele, mostly representing high FMR1 genotypes/sub-genotypes, varied amongst the two groups as well (Mann-Whitney U = Mean Rank 231.18low, 260.75high; Z = −0.069; P = 0.07) but failed to reach statistical significance (Figure 2a). Figure 2 presents distributions of individual CGG n in both study groups.
This study was initiated to determine whether prematurely diminished functional ovarian reserve in women with BRCA1/2 mutations, was, as had been suggested, a newly discovered association with BRCA1/2  or due to overlapping associations with FMR1 genotypes and sub-genotypes, previously demonstrated to affect ovarian reserve –. Here reported finding answered this question rather unequivocally by demonstrating that BRCA1/2 mutations were, practically, almost exclusively only associated with the het-norm/low FMR1 sub-genotype. Since this sub-genotype has been associated with prematurely diminished ovarian reserve and lower pregnancy chances with IVF in all races , , it appears likely that the reported association of BRCA1 with premature diminished ovarian reserve  is actually FMR1-mediated.
The here observed distribution of FMR1 genotypes and sub-genotypes in BRCA1/2 carriers came, however, as a complete surprise since no other previously investigated patient population had demonstrated a FMR1 genotype/sub-genotype distribution as here observed amongst BRCA1/2 carriers.
The most likely explanation for complete absence of het-norm/high, minimal presence of norm genotypes and highly excessive presence of het-norm/low FMR1 sub-genotypes in BRCA1/2-positive women is principal embryo-lethality of BRCA1/2 mutations. Only if a human embryo carries a low (CGG n<26) sub-genotype allele is such an embryo able to overcome the BRCA1/2-associated embryo lethality. Such low sub-genotypes can be present in het-norm/low, hom-low/low and hom-high/low FMR1 sub-genotypes, combined, representing approximately 25 percent of all women (Figure 1) , . In other words, only approximately one in four human embryos with BRCA1/2 mutations will survive–a previously unreported cause of human embryo mortality.
An alternative explanation for here reported findings would be that BRCA1/2 mutations, somehow, are able to influence CGG triple nucleotide repeats (CGGn) on the FMR1 gene. Such an explanation, however, appears unlikely.
BRCA1/2 mutations have never before in humans been reported to be embryo-lethal. Some homozygous BRCA1/2 mouse models, however, proved embryo-lethal, though with great variability in phenotypes and in rescue of embryonic lethality on a p53-null background . BRCA1/2 genetically interacts with the p53 pathway, at least partially explaining the so-called “BRCA paradox,” defined by BRCA-deficient tumor cells rapidly proliferating, while BRCA-deficient embryos suffer from proliferation defects  (for further detail see later). In animal experiments, p53-nullizygousity can rescue some BRCA1 mouse mutants – but may only delay lethality , . The possibility of BRCA1/2 being embryo lethal in humans, therefore, appears realistic.
This then raises the next important question: how do low FMR1 sub-genotypes (CGG n<26) rescue embryos from BRCA1/2 lethality? The answer will require a better understanding of the FMR1 gene. Ovarian function associations of het sub-genotypes have been reasonably well defined , , . The much rarer, hom sub-genotypes are less well defined and, here, had to be collapsed into a single group with potentially functionally opposing sub-genotypes.
Evolutionary, the norm genotype of FMR1, with both alleles in normal range (CGG n = 26–34), appears to represent the original (“ur”-) FMR1 gene. Whether one or both alleles mutated outside of normal range, then determined het and hom genotypes. Expansions beyond CGG n>34 generated high sub-genotypes, primarily known for neuro-psychiatric risks in association with traditional premutation and full mutation genotypes , , . Contractions to CGG n<26 resulted in low sub-genotypes with, as here demonstrated, rescue ability from embryo lethality by BRCA1/2 mutations but increased risk towards autoimmunity , .
It is remarkable that not a single BRCA1/2 patient demonstrated in this study a high (CGG n>34) sub-genotype, strongly suggesting that high FMR1 sub-genotypes do not protect from embryo lethality. This is, however, not the first observation where low and high sub-genotypes of the FMR1 gene denote opposing effects: het-norm/high was shown to be protective against autoimmunity, while het-norm/low promoted significant autoimmune risk , . Since higher prevalence of autoimmunity in women has remained unexplained , the FMR1 gene may have here an additional role to play.
Similar observations were recently also made for the polymorphic CAG repeat unit, which encodes an uninterrupted polyglutamine (polyQ) tract in the N-terminal transactivation domain of the androgen receptor. This is another prominent gene, characterized by ability to expand or contract trinucleotide repeat sequences from a normal range of CAG n = 6–39 . Like with the FMR1 gene, initial investigations only considered the gene’s expansion risk to be clinically significant. A recent study, however, for the first time found shorter CAG repeats associated with cryptorchidism risks .
Located at the 5′ untranslated exon 1 on the X chromosome at Xq27.3, a region now considered associated with autoimmune risks , the FMR1 gene appeared positioned at crossroads of autoimmunity and reproduction . Based on here reported data the gene, now, however, appears located at triple crossroads of autoimmunity, cancer and reproduction. Here is why: Lifetime risk for breast cancer of 1 per 8.2 women (12.2% per woman) increases in presence of BRCA1/2 mutations approximately five-fold to ca. 60 percent (22). BRCA1/2 mutations, thus, account for 5–10 percent of all breast cancers (23). Lifetime ovarian cancer risk of ca. 1.4 percent in presence of BRCA1/2 mutations increases 10.7- to 28.6-fold to a 15 to 40 percent range . BRCA1/2, thus, accounts for 10 to 15 percent of all ovarian cancer risk , with other cancers also demonstrating increased prevalence in association with BRCA1 (uterine cervix and corpus, pancreas and colon) ,  and BRCA2 (pancreas, stomach, gallbladder, bile ducts and malignant melanoma) .
Because of high costs, BRCA1/2 mutation screening is currently restricted to families at excessive risk for breast and ovarian cancers. Here presented data, if confirmed, suggest a potentially lower cost screening option via assessment of the FMR1 gene since BRCA1/2 positive women can, almost exclusively, be expected amongst approximately 25 percent of females with a low FMR1 sub-genotype. The remaining approximately 75 percent of women, in turn, could be considered at only minimal risk to be BRCA1/2 carriers.
The estimated population frequency for BRCA1/2 mutations (0.024 to 0.04%) in recessive and polygenic models, respectively , is held responsible for 5 to10 percent of all breast cancers and 10 to 15 percent of all ovarian cancer risk . Extrapolating, the het-norm/low FMR1 sub-genotype, representing approximately 78.8 percent of BRCA1/2 patients, spread over only ca. a quarter of all women, would reflect 3.95 to 7.9 percent of all breast and 7.9 to 11.9 percent of ovarian cancer risk, concentrated in only approximately a quarter of the female population.
Hom-low FMR1 sub-genotypes, hom-high low and hom-low/low, in this study not separately assessed, likely, would add a few percentage points.
FMR1 genotypes and sub-genotypes  and prevalence of BRCA1/2 mutations – vary in different races/ethnicities. Interestingly, so do female cancers , , autoimmunity  and female infertility prevalence . It is tempting to hypothesize that these observations may be associated.
Since BRCA in normal cells induces growth arrest, while promoting tumor formation in BRCA mutation carriers, Evers and Jonkers pointed at the likely presence of secondary suppressor mutations, which may overcome BRCA-associated arrests during BRCA-associated tumorigenesis in association with the so-called “BRCA paradox” . With FMR1 apparently at crossroads of reproduction, immunology and cancer, it is tempting to hypothesize about such, each other opposing, functions for the two het sub-genotypes of FMR1, het-norm/high and het-norm/low. Within such a context low FMR1 alleles not only may overcome embryo lethality (i.e., growth arrest) in human embryos but may also have a similar function in the induction of BRCA1/2-associated malignancies by overcoming the natural growth arrest functions of BRCA1/2 by inducing tumor growth. Appropriate studies in BRCA1/2-associated tumor models, therefore, would be of interest.
Confirming such a growth arrest-reversing function of low FMR1 alleles would, of course, have major relevance for the current understanding of tumor induction and diagnostic tumor risk assessments. Most importantly, however, one would have to conclude that in so-called BRCA1/2-associated tumors (like in premature decreased ovarian reserve) low FMR1 alleles, and not BRCA mutation, are the real culprits. Finally, confirmation of such an FMR1 function would rekindle decades-old considerations about common biological processes in pregnancy and malignancy , .
Here investigated patients were European and American, and, therefore, may reflect genetic diversities. Furthermore, their retroactive evaluations may have resulted in selection biases. Assay performance in different laboratories may have resulted in divergent results between study groups. Similarities in FMR1 genotype and sub-genotype distribution between Austrian and U.S. control groups (for detail see Materials and Methods), however, practically rule out significant statistical impacts from laboratory or patient variability.
Remarkable statistical clarity of here reported results, therefore, strongly supports reported assertions, suggesting major new biological and clinical importance for FMR1 and BRCA1/2 mutations, deserving of further exploration.
Conceived and designed the experiments: AW DHB NG. Performed the experiments: DHB AK. Analyzed the data: DHB AK AW NG. Contributed reagents/materials/analysis tools: MKT CFS KW. Wrote the paper: NG. Contributed to availability of Austrian patient data: MKT CFS KW. Coordination between Austrian and US investigators: AW.
- 1. Willemsen R, Levenga J, Oostra BA (2011) CGG repeat in the FMR1 gene: size matters. Clin Genet 80: 214–25. doi: 10.1111/j.1399-0004.2011.01723.x
- 2. Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, et al. (2007) The FMR1 premutation and reproduction. Fertil Steril 87: 456–465. doi: 10.1016/j.fertnstert.2006.09.004
- 3. Gleicher N, Weghofer A, Barad DH (2010) Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reprod Biomed Online 20: 768–75. doi: 10.1016/j.rbmo.2010.02.020
- 4. Gleicher N, Weghofer A, Lee IH, Barad DH (2010) FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance. PLoS ONE 5: e15303. doi: 10.1371/journal.pone.0015303
- 5. Gleicher N, Weghofer A, Barad DH (2010) Effects of race/ethnicity on triple CGG counts in the FMR1 gene in infertile women and egg donors. Reprod Biomed Online 20: 485–491. doi: 10.1016/j.rbmo.2009.12.017
- 6. Gleicher N, Weghofer A, Lee IH, Barad DH (2011) Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS ONE 6: e18781. doi: 10.1371/journal.pone.0018781
- 7. Chen LS, Tassone FT, Sahota P, Hagerman PJ (2003) The (CGG)n repeat element within the 5’ untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum Molec Genet 12: 3067–74. doi: 10.1093/hmg/ddg331
- 8. Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28: 240–4. doi: 10.1200/jco.2009.24.2057
- 9. Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pages S, et al. (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62: 369–76. doi: 10.1006/geno.1999.6026
- 10. Sanger F, Nickelen S, Coulson R (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463–7. doi: 10.1073/pnas.74.12.5463
- 11. Petek E, Kroisel PM, Schuster M, Zierler H, Wagner K (1999) Mosaicism in a fragile X male including a de novo deletion in the FMR1 gene. Am. J Med Genet 84: 229–32. doi: 10.1002/(sici)1096-8628(19990528)84:3<229::aid-ajmg13>3.3.co;2-k
- 12. Evers B, Jonkers J (2006) Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25: 5885–97. doi: 10.1038/sj.onc.1209871
- 13. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA (1997) p53 mutations in BRCA1-associated familial breast cancer. Lancet 350: 638–9. doi: 10.1016/s0140-6736(05)63327-2
- 14. Xu CF, Chambers JA, Nicolai H, Brown MA, Hujeirat Y, et al. (1997) Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes Chromosomes Cancer 18: 102–10. doi: 10.1002/(sici)1098-2264(199702)18:2<102::aid-gcc4>3.3.co;2-a
- 15. Cao L, Li W, Kim S, Brodie SG, Deng CX (1993) Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 17: 201–13. doi: 10.1101/gad.1050003
- 16. Hakem R, de la Pompa JL, Elia A, Potter J, Mark TW (1997) Partial rescue of Brca1 (5–6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 16: 298–302. doi: 10.1038/ng0797-298
- 17. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A (1997) Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226–41. doi: 10.1101/gad.11.10.1226
- 18. Krausz C (2012) An encore for the repeats: New insights into an old genetic variant. J Clin Endocrinol Metab 97: 764–767. doi: 10.1210/jc.2012-1130
- 19. Gleicher N, Barad DH (2007) Gender as risk factor for autoimmune diseases. J Autoimmun 28: 1–6. doi: 10.1016/j.jaut.2006.12.004
- 20. Davis-Dao C, Koh CJ, Hardy BE, Chang A, Kim SS, et al.. (2012) Shorter androgen receptor CAG repeat lengths associated with cryptorchidism risk among Hispanic white boys. J Clin Endocrinol Metab 97;E393–E399.
- 21. Gleicher N, Weghofer A, Barad DH (2012) Cutting edge assessment of the impact of autoimmunity on female reproductive success. J Autoimmun 38: J74–J80. doi: 10.1016/j.jaut.2011.05.016
- 22. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review 1975–2007, Bethesda, MD, National Cancer Institute (Accessed at http://seer.cancer.gov/csr/1975_2007/.)
- 23. Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Human Genetics 124: 31–42. doi: 10.1007/s00439-008-0529-1
- 24. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, et al. (2007) Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 44: 467–71. doi: 10.1136/jmg.2006.048173
- 25. Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Nat Cancer Inst 94: 1358–65. doi: 10.1093/jnci/94.18.1358
- 26. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Nat Cancer Inst 91: 1310–6. doi: 10.1093/jnci/91.15.1310
- 27. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, et al. (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21: 1–18. doi: 10.1002/gepi.1014
- 28. John EM, Miron A, Gong G, Phipps AI, Felberg A, et al. (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298: 2869–76. doi: 10.1001/jama.298.24.2869
- 29. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, et al. (2007) BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25: 4635–41. doi: 10.1200/jco.2006.10.4703
- 30. Malone KE, Daling JR, Doody DR, Hsu L, Bernstin L, et al. (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66: 8297–308. doi: 10.1158/0008-5472.can-06-0503
- 31. Ademuyiwa FO, Edge SB, Erwin DO, Orom H, Ambrosone CB, et al. (2011) Breast cancer racial disparities: unanswered questions. Cancer Res 71: 640–4. doi: 10.1158/0008-5472.can-10-3021
- 32. Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM (2011) Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol Nov 21 [Epub ahead of print].
- 33. Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T (2007) Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res Clin Pract 77 Suppl 1S116–21. doi: 10.1016/j.diabres.2007.01.044
- 34. Gleicher N, Siegel I, Francus K (1980) Common denominators of pregnancy and malignancy. Mt Sinai J Med 47: 511–520.
- 35. Gleicher N, Siegel I (1981) Common denominators of pregnancy and malignancy. Prog Clin Biol Res 70: 339–353.